In 2010, the global cancer market was valued at $54 billion, with forecasted Compound Annual Growth Rate (CAGR) growth to $81 billion by 2016. The seven major cancer markets (US, France, Germany, Italy, Spain, United Kingdom and Japan) represented ~79% of the 2010 global cancer market ($43 billion). The US dominated 2010 sales with a market share of 38.5% and the leading ten companies of the global cancer market represented 87.1% ($47 billion) of the total market.
—Source: The Cancer Market Outlook to 2016; Competitive landscape, market size, pipeline analysis, and growth opportunities, June 2011
Non-Small-Cell Lung Cancer
The global Non-Small-Cell Lung Cancer (NSCLC) drug market is projected to increase from $4.3 billion in 2009 to $6.9 billion in 2019 with a CAGR of 4.84% in the major market segments of the United States, 5EU [France, Germany, Italy, Spain, United Kingdom] and Japan.
—Source: Non Small Cell Lung Cancer Market – Global Industry Size, Share, Trends, Analysis And Forecasts 2012 – 2018, Transparency Market Research
Due to high disease incidence and higher drug prices compared with the 5EU, Japan, and China, the US is the largest NSCLC market. Increasing disease incidence cases driven by an aging population, the launch of new therapies that target patient segments with high unmet need, and identification of additional patients through increased testing will drive sales of NSCLC therapies.
—Source: PharmaPoint: Non-Small Cell Lung Cancer – US Drug Forecast and Market Analysis to 2022